Pictor’s new product launch - here and in U.S.
Readers of my newsletters may recall the very successful Pictor Offer that was completed last year.
Readers of my newsletters may recall the very successful Pictor Offer that was completed last year.
Following new investment of over $9 million – from the above and from
former Morrison & Co CEO Marko Bogoievski, and specialist growth
investor K One W One Limited – Pictor is now announcing a $5 million
extension tor that round.
This will enable Pictor to continue to accelerate its R&D and
Commercial efforts, and to successfully launch 3 more diagnostic
products over the next 6 months.
The proceeds from this Offer have been allocated to the development of 4
new products about to be released. This was announced in the media last week and they include the COVID antibody test in New Zealand with Rako Science and APHG.
The test is now set to launch in the U.S. this week with two U.S. companies – Mobility Health and Integrity Laboratories.
The problem
The understanding of livestock diseases has improved over time, but unfortunately the way in which they can be detected has not.
Current tests still rely upon using one marker of a disease for
detection, which often can only identify infected animals with
late-stage disease. Mycoplasma Bovis and Johne's Disease are examples of two diseases that have a substantial impact on productivity in Livestock.
However the control of these diseases is hampered by diagnostic tests that have poor sensitivity.
Early detection the solution
Pictor has developed an innovative approach to Animal Health disease
detection where multiple markers of disease are used in a single test to
identify infections much earlier than existing tests.
They now have two early detection tests for Mycoplasma Bovis and Johne's
Disease which on track for launch by Q2, 2023. The launch of both will
initially be here and in Australia. with the Company targeting launches
in select Global markets by Q4, 2023.
The Company has also developed novel diagnostic tests that allow up to 9
diseases or biomarkers to be detected from one sample. This
high-efficacy diagnostic multiplexed platform can identify infectious
and complex diseases for human and animal health.
The timing
After more the five years of R&D, Pictor has developed a deep
commercial pipeline of use cases for their patented multiplexed
diagnostics platform and is now close to achieving commercial milestones
in several human and animal health products within the next 6 to 12
months.
Upon achieving these milestones, Pictor will accelerate the
commercialisation of further animal and human health products they
already have in the pipeline and be able to bring forward R&D on
future products and applications.
Want to know more?
An Information Memorandum, an investor slide deck, and a subscription agreement are all available for intending investors.
So if you’re interested in investing, or would like more information, reply to this email, or give me a call on +64 21 902 901.
.............................................................................................................................................................................................................
The above investment is not an offer of financial products that
requires disclosure under the Financial Markets Conduct Act 2013 (Act)
and is available only to wholesale investors as defined by that Act. It
is intended for distribution only to selected people to whom, under the
relevant laws, it can be lawfully distributed. It cannot be distributed
in any other jurisdiction, or to any other people. It is not an offer or
solicitations in any jurisdiction in which such offers or solicitations
are not authorised, or in which the person making such offers or
solicitations are not qualified to do so, or to any person to whom it is
unlawful to make such offers or solicitations. Any representation to
the contrary would be unlawful. No action has been taken by any person
that would permit a public offering in any jurisdiction where action for
that purpose would be required.
Cheers
John Paine B.Sc., Dip BIA
TBK Capital Limited
Level 10,120 Albert Street
Auckland 1010, New Zealand
Phone +64 9 307 3257
Mobile +64 21 902 901
Email john.paine@tbkcapital.co.nz
For more information, please click the contact button below to send us a message.
⇑ back to top